CN102056903A - 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药 - Google Patents
抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药 Download PDFInfo
- Publication number
- CN102056903A CN102056903A CN2009801216814A CN200980121681A CN102056903A CN 102056903 A CN102056903 A CN 102056903A CN 2009801216814 A CN2009801216814 A CN 2009801216814A CN 200980121681 A CN200980121681 A CN 200980121681A CN 102056903 A CN102056903 A CN 102056903A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- disease
- group
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c1c(C2*C2)ccc(N)c1 Chemical compound *c1c(C2*C2)ccc(N)c1 0.000 description 12
- KMAQMONXBRTOAT-UHFFFAOYSA-N Cc(cc1Br)cc(-c2n[nH]c(-c3ccc4OCOc4c3)c2)c1O Chemical compound Cc(cc1Br)cc(-c2n[nH]c(-c3ccc4OCOc4c3)c2)c1O KMAQMONXBRTOAT-UHFFFAOYSA-N 0.000 description 1
- JTHWYHUIABKNQI-UHFFFAOYSA-N Cc1cccc(-c2cc(-c(cc3)cc4c3OCO4)n[nH]2)c1 Chemical compound Cc1cccc(-c2cc(-c(cc3)cc4c3OCO4)n[nH]2)c1 JTHWYHUIABKNQI-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/333—Radicals substituted by oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Abstract
Description
Claims (19)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08010458 | 2008-06-09 | ||
EP08010458.1 | 2008-06-09 | ||
PCT/EP2009/004144 WO2010000372A2 (en) | 2008-06-09 | 2009-06-09 | New drug for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102056903A true CN102056903A (zh) | 2011-05-11 |
CN102056903B CN102056903B (zh) | 2015-04-15 |
Family
ID=40942347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980121681.4A Active CN102056903B (zh) | 2008-06-09 | 2009-06-09 | 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药 |
Country Status (21)
Country | Link |
---|---|
US (3) | US20110293520A1 (zh) |
EP (3) | EP2684873B1 (zh) |
JP (3) | JP5896739B2 (zh) |
KR (1) | KR101787112B1 (zh) |
CN (1) | CN102056903B (zh) |
AU (1) | AU2009266098B2 (zh) |
BR (2) | BR122019022071B8 (zh) |
CA (1) | CA2726999C (zh) |
CL (2) | CL2010001369A1 (zh) |
DK (2) | DK2684873T3 (zh) |
ES (2) | ES2862923T3 (zh) |
HU (2) | HUE053352T2 (zh) |
IL (1) | IL208377A (zh) |
MX (1) | MX339144B (zh) |
NZ (1) | NZ588442A (zh) |
PL (2) | PL2684873T3 (zh) |
PT (2) | PT2684873T (zh) |
RU (1) | RU2531915C2 (zh) |
TR (1) | TR201904041T4 (zh) |
WO (1) | WO2010000372A2 (zh) |
ZA (1) | ZA201008820B (zh) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104693121A (zh) * | 2014-11-14 | 2015-06-10 | 中山大学 | 一类具有抗老年痴呆活性的吡唑类化合物、制备方法与应用 |
CN108473516A (zh) * | 2015-12-14 | 2018-08-31 | 马克斯·普朗克科学促进协会 | 3,5-二苯基-二唑化合物的水溶性衍生物 |
CN109726510A (zh) * | 2019-01-23 | 2019-05-07 | 山东大学 | 一种蛋白质糖化位点鉴定方法 |
CN111138376A (zh) * | 2019-12-24 | 2020-05-12 | 中山大学 | 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用 |
CN111848516A (zh) * | 2020-08-04 | 2020-10-30 | 山东大学 | 溴酚-吡唑啉类化合物及其合成方法和应用 |
CN113045507A (zh) * | 2021-03-04 | 2021-06-29 | 中山大学南方学院 | 一种3,4-二羟基苯甲酸甲酯衍生物及其制备方法与应用 |
CN114573570A (zh) * | 2022-02-21 | 2022-06-03 | 中山大学 | 一类α-突触核蛋白靶向化合物及其制备方法和应用 |
CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
CN115650957A (zh) * | 2022-09-16 | 2023-01-31 | 中山大学 | 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8829198B2 (en) * | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
US8916598B2 (en) | 2003-05-30 | 2014-12-23 | Proteotech Inc | Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies |
WO2009111611A2 (en) | 2008-03-05 | 2009-09-11 | Proteotech Inc. | Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes |
JP5361316B2 (ja) * | 2008-10-02 | 2013-12-04 | 株式会社タムラ製作所 | 表面処理剤、プリント回路基板およびその製造方法 |
LT2563920T (lt) * | 2010-04-29 | 2017-05-25 | Ionis Pharmaceuticals, Inc. | Transtiretino raiškos moduliavimas |
US8865754B2 (en) | 2011-03-03 | 2014-10-21 | Proteotech Inc. | Compounds for the treatment of neurodegenerative diseases |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
GB201116017D0 (en) * | 2011-09-16 | 2011-10-26 | Univ Surrey | Bi-aromatic and tri-aromatic compounds as nadph oxidase inhibitors |
US10709688B2 (en) | 2016-03-31 | 2020-07-14 | Tohoku University | Agent for treating synucleinopathy |
GB201611840D0 (en) * | 2016-07-07 | 2016-08-24 | Univ Court Of The Univ Of Edinburgh The | Alpha-synuclein detection assay |
KR101956302B1 (ko) * | 2016-11-30 | 2019-03-11 | 연세대학교 산학협력단 | 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물 |
KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
CA3062749A1 (en) * | 2017-05-12 | 2018-11-15 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Compounds for use in the treatment or prevention of melanoma |
CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
MX2022005914A (es) * | 2019-11-19 | 2022-08-04 | Modag Gmbh | Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina. |
CN113552102B (zh) * | 2021-07-16 | 2022-05-17 | 上海交通大学 | 一种基于荧光相关光谱检测有机溶剂诱导蛋白聚集的药物筛选方法 |
EP4173485A1 (en) | 2021-10-27 | 2023-05-03 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Protein aggregation inhibiting compounds for plant disease control |
WO2023166045A1 (en) * | 2022-03-01 | 2023-09-07 | Modag Gmbh | Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use |
US11919872B1 (en) | 2023-10-11 | 2024-03-05 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
US11897850B1 (en) | 2023-10-11 | 2024-02-13 | King Faisal University | N′-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-4-methoxybenzimidamide as an antimicrobial compound |
US11912675B1 (en) | 2023-10-11 | 2024-02-27 | King Faisal University | N'-(2-(5-(4-chlorophenyl)-1,3,4-oxadiazol-2-ylthio)acetoxy)-3,4-dimethoxybenzimidamide as an antimicrobial compound |
US11891366B1 (en) | 2023-10-12 | 2024-02-06 | King Faisal University | 4-methoxy-n′-(2-(5-phenyl-1,3,4-oxadiazol-2-ylthio)acetoxy)benzimidamide as an antimicrobial compound |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04124178A (ja) * | 1990-09-12 | 1992-04-24 | Sds Biotech Kk | 複素環式化合物および該化合物を含有する除草剤 |
CN1355790A (zh) * | 1999-06-10 | 2002-06-26 | 沃尼尔·朗伯公司 | 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法 |
US20040019113A1 (en) * | 2001-12-26 | 2004-01-29 | Geltex Pharmaceuticals, Inc. | Phosphate transport inhibitors |
WO2004080972A1 (en) * | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
WO2006109680A1 (ja) * | 2005-04-07 | 2006-10-19 | Nippon Kayaku Kabushiki Kaisha | 3,5-ジフェニルピラゾール類縁体の抗腫瘍剤としての用途 |
US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
CN101155602A (zh) * | 2005-02-04 | 2008-04-02 | 通用电气健康护理有限公司 | 包含胱天蛋白酶-3底物的成像剂 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL126440C (zh) * | 1958-08-20 | |||
CH426848A (de) * | 1960-03-01 | 1966-12-31 | Ciba Geigy | Verfahren zur Herstellung von 1,3,4-Thiadiazolen |
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
FR2104932A1 (en) * | 1970-09-08 | 1972-04-28 | Ferlux | O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc |
US3907824A (en) * | 1973-06-18 | 1975-09-23 | American Cyanamid Co | Preparation of 1-alkyl-3,5-diphenylpyrazoles and 1,2-dialkyl-3,5-diphenylpyrazolium salts |
ZA744908B (en) * | 1973-09-17 | 1975-08-27 | American Cyanamid Co | Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
ATE12348T1 (de) | 1980-11-10 | 1985-04-15 | Gersonde Klaus Prof Dr | Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens. |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
JPS58118008A (ja) | 1982-01-06 | 1983-07-13 | Nec Corp | デ−タ処理装置 |
EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0142641B1 (de) | 1983-09-26 | 1991-01-16 | Udo Dr. Ehrenfeld | Mittel und Erzeugnis für die Diagnose und Therapie von Tumoren sowie zur Behandlung von Schwächen der zelligen und humoralen Immunabwehr |
DE3474511D1 (en) | 1983-11-01 | 1988-11-17 | Terumo Corp | Pharmaceutical composition containing urokinase |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
PH27357A (en) * | 1989-09-22 | 1993-06-21 | Fujisawa Pharmaceutical Co | Pyrazole derivatives and pharmaceutical compositions comprising the same |
DE4126543A1 (de) | 1991-08-10 | 1993-02-11 | Chem & Pharm Patent Hold Ltd | 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel |
DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
AU2001231202A1 (en) | 2000-01-28 | 2001-08-07 | Akkadix Corporation | Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives |
DK2264018T3 (en) * | 2000-08-24 | 2015-05-11 | Univ Pittsburgh | Thioflavin derivatives for use in diagnosis of Alzheimer's disease |
EP1492487B1 (en) * | 2002-03-08 | 2009-11-11 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
WO2003093252A1 (en) * | 2002-05-01 | 2003-11-13 | Merck Sharp & Dohme Limited | Heteroaryl substituted spirocyclic sulfamides for inhibition of gamma secretase |
US20070276034A1 (en) | 2002-05-31 | 2007-11-29 | Luke Esposito | Compounds, compositions and methods for the treatment of synucleinopathies |
SI2527315T1 (sl) * | 2002-05-31 | 2014-06-30 | Proteotech Inc., | Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen |
US8829198B2 (en) * | 2007-10-31 | 2014-09-09 | Proteotech Inc | Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies |
TW200413009A (en) * | 2002-10-04 | 2004-08-01 | Univ Pennsylvania | Biphenyls and fluorenes as imaging agents in alzheimer's disease |
AU2003271117A1 (en) * | 2002-10-09 | 2004-05-04 | Ssp Co., Ltd. | Novel pyrazole compounds having antifungal activity |
GB0225474D0 (en) * | 2002-11-01 | 2002-12-11 | Merck Sharp & Dohme | Therapeutic agents |
GB0303503D0 (en) | 2003-02-14 | 2003-03-19 | Novartis Ag | Organic compounds |
HUE055434T2 (hu) * | 2003-04-11 | 2021-11-29 | Ptc Therapeutics Inc | 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére |
US7220745B2 (en) | 2003-05-15 | 2007-05-22 | Rigel Pharmaceuticals | Heterocyclic compounds useful to treat HCV |
JP2007530690A (ja) * | 2004-03-29 | 2007-11-01 | メルク エンド カムパニー インコーポレーテッド | 11−β−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのジアリールトリアゾール |
WO2005113519A1 (en) * | 2004-05-14 | 2005-12-01 | Irm Llc | Compounds and compositions as ppar modulators |
RU2007131043A (ru) * | 2005-02-14 | 2009-03-20 | Вайет (Us) | Азолилацилгуанидины, применяемые в качестве ингибиторов бета-секретазы |
AU2006201739A1 (en) * | 2005-05-05 | 2006-11-23 | The University Of North Carolina At Chapel Hill | Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles |
WO2007002540A2 (en) | 2005-06-24 | 2007-01-04 | Kung Hank F | Radiolabeled-pegylation of ligands for use as imaging agents |
US8022075B2 (en) * | 2005-11-30 | 2011-09-20 | Fujifilm Ri Pharma Co., Ltd. | Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition |
PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
US20080015193A1 (en) * | 2006-06-20 | 2008-01-17 | Mendoza Jose S | Certain azoles exhibiting ATP-utilizing enzyme inhibitory activity, compositions, and uses thereof |
EP2144507A4 (en) | 2007-04-19 | 2010-05-26 | Univ Pennsylvania | DIPHENYL-HETEROARYL DERIVATIVES AND THEIR USE FOR BINDING AND IMAGING AMYLOID PLATES |
JP2009203166A (ja) * | 2008-02-26 | 2009-09-10 | Nagasaki Univ | ジフェニルオキサジアゾール誘導体含有診断用組成物 |
EA021672B1 (ru) * | 2008-05-14 | 2015-08-31 | Дзе Скриппс Рисёч Инститьют | Модуляторы рецепторов сфингозин-1-фосфата и их применение |
CN102047061A (zh) * | 2008-05-30 | 2011-05-04 | 福斯特韦勒能源股份公司 | 通过氧化燃料燃烧发电的方法和系统 |
-
2009
- 2009-06-09 PL PL13176579T patent/PL2684873T3/pl unknown
- 2009-06-09 CN CN200980121681.4A patent/CN102056903B/zh active Active
- 2009-06-09 PL PL09772072T patent/PL2307381T3/pl unknown
- 2009-06-09 HU HUE09772072A patent/HUE053352T2/hu unknown
- 2009-06-09 ES ES09772072T patent/ES2862923T3/es active Active
- 2009-06-09 CA CA2726999A patent/CA2726999C/en active Active
- 2009-06-09 DK DK13176579.4T patent/DK2684873T3/en active
- 2009-06-09 BR BR122019022071A patent/BR122019022071B8/pt active IP Right Grant
- 2009-06-09 NZ NZ588442A patent/NZ588442A/xx unknown
- 2009-06-09 KR KR1020117000508A patent/KR101787112B1/ko active IP Right Grant
- 2009-06-09 PT PT13176579T patent/PT2684873T/pt unknown
- 2009-06-09 TR TR2019/04041T patent/TR201904041T4/tr unknown
- 2009-06-09 EP EP13176579.4A patent/EP2684873B1/en active Active
- 2009-06-09 RU RU2010154272/04A patent/RU2531915C2/ru active
- 2009-06-09 AU AU2009266098A patent/AU2009266098B2/en active Active
- 2009-06-09 MX MX2010012655A patent/MX339144B/es active IP Right Grant
- 2009-06-09 ES ES13176579T patent/ES2714453T3/es active Active
- 2009-06-09 EP EP13176577.8A patent/EP2687513B1/en active Active
- 2009-06-09 BR BRPI0913609A patent/BRPI0913609B8/pt active IP Right Grant
- 2009-06-09 EP EP09772072.6A patent/EP2307381B1/en active Active
- 2009-06-09 WO PCT/EP2009/004144 patent/WO2010000372A2/en active Application Filing
- 2009-06-09 JP JP2011512038A patent/JP5896739B2/ja active Active
- 2009-06-09 DK DK09772072.6T patent/DK2307381T3/da active
- 2009-06-09 US US12/996,833 patent/US20110293520A1/en not_active Abandoned
- 2009-06-09 PT PT97720726T patent/PT2307381T/pt unknown
- 2009-06-09 HU HUE13176579A patent/HUE043090T2/hu unknown
-
2010
- 2010-10-03 IL IL208377A patent/IL208377A/en active IP Right Grant
- 2010-12-07 CL CL2010001369A patent/CL2010001369A1/es unknown
- 2010-12-08 ZA ZA2010/08820A patent/ZA201008820B/en unknown
-
2014
- 2014-02-03 CL CL2014000270A patent/CL2014000270A1/es unknown
-
2015
- 2015-12-16 JP JP2015245186A patent/JP6307060B2/ja active Active
- 2015-12-16 JP JP2015245187A patent/JP6276744B2/ja active Active
- 2015-12-22 US US14/978,964 patent/US10071966B2/en active Active
-
2018
- 2018-08-03 US US16/054,416 patent/US10435373B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04124178A (ja) * | 1990-09-12 | 1992-04-24 | Sds Biotech Kk | 複素環式化合物および該化合物を含有する除草剤 |
CN1355790A (zh) * | 1999-06-10 | 2002-06-26 | 沃尼尔·朗伯公司 | 采用二氢异吲哚衍生物抑制淀粉样蛋白聚集和使淀粉样蛋白沉积成像的方法 |
US20040019113A1 (en) * | 2001-12-26 | 2004-01-29 | Geltex Pharmaceuticals, Inc. | Phosphate transport inhibitors |
WO2004080972A1 (en) * | 2003-03-12 | 2004-09-23 | Vertex Pharmaceuticals Incorporated | Pirazole modulators of atp-binding cassette transporters |
CN101155602A (zh) * | 2005-02-04 | 2008-04-02 | 通用电气健康护理有限公司 | 包含胱天蛋白酶-3底物的成像剂 |
WO2006109680A1 (ja) * | 2005-04-07 | 2006-10-19 | Nippon Kayaku Kabushiki Kaisha | 3,5-ジフェニルピラゾール類縁体の抗腫瘍剤としての用途 |
US20070197532A1 (en) * | 2005-11-18 | 2007-08-23 | Cao Sheldon X | Glucokinase activators |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104693121A (zh) * | 2014-11-14 | 2015-06-10 | 中山大学 | 一类具有抗老年痴呆活性的吡唑类化合物、制备方法与应用 |
CN108473516A (zh) * | 2015-12-14 | 2018-08-31 | 马克斯·普朗克科学促进协会 | 3,5-二苯基-二唑化合物的水溶性衍生物 |
CN108473516B (zh) * | 2015-12-14 | 2021-06-18 | 马克斯·普朗克科学促进协会 | 3,5-二苯基-二唑化合物的水溶性衍生物 |
CN109726510A (zh) * | 2019-01-23 | 2019-05-07 | 山东大学 | 一种蛋白质糖化位点鉴定方法 |
CN111138376A (zh) * | 2019-12-24 | 2020-05-12 | 中山大学 | 一种3,5-二取代苯基-1,2,4-噁二唑衍生物及其制备方法和应用 |
CN111848516A (zh) * | 2020-08-04 | 2020-10-30 | 山东大学 | 溴酚-吡唑啉类化合物及其合成方法和应用 |
CN113045507A (zh) * | 2021-03-04 | 2021-06-29 | 中山大学南方学院 | 一种3,4-二羟基苯甲酸甲酯衍生物及其制备方法与应用 |
CN114573570A (zh) * | 2022-02-21 | 2022-06-03 | 中山大学 | 一类α-突触核蛋白靶向化合物及其制备方法和应用 |
CN114573570B (zh) * | 2022-02-21 | 2023-05-30 | 中山大学 | 一类α-突触核蛋白靶向化合物及其制备方法和应用 |
CN115337301A (zh) * | 2022-07-22 | 2022-11-15 | 汕头大学医学院第一附属医院 | Anle138b在制备改善饮食诱导胰岛素抵抗药物中的应用 |
CN115650957A (zh) * | 2022-09-16 | 2023-01-31 | 中山大学 | 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用 |
CN115650957B (zh) * | 2022-09-16 | 2023-12-15 | 中山大学 | 一类靶向α-突触核蛋白的蛋白水解嵌合体及其应用 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102056903B (zh) | 抑制与蛋白聚集有关的疾病和/或神经变性疾病中涉及的蛋白聚集的新药 | |
Mandal et al. | Design and validation of bicyclic iminopyrimidinones as beta amyloid cleaving enzyme-1 (BACE1) inhibitors: conformational constraint to favor a bioactive conformation | |
Lu et al. | Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice | |
KR20060023529A (ko) | 화합물 및 아밀로이드 베타를 변조하는데 있어서 그의 용도 | |
AU1290700A (en) | Methods and compositions for restoring conformational stability of a protein of the p53 family | |
CN101896068A (zh) | 抗凋亡蛋白的萘基抑制剂 | |
JP2012522017A (ja) | 診断適用および臨床適用のための癌胎児抗原/未熟ラミニン受容体抗体 | |
Kamenecka et al. | Potent anti-diabetic actions of a novel non-agonist PPARγ ligand that blocks cdk5-mediated phosphorylation | |
Akasaka et al. | In Vivo Near-Infrared Fluorescence Imaging Selective for Soluble Amyloid β Aggregates Using y-Shaped BODIPY Derivative | |
US20180036433A1 (en) | Compounds for the diagnosis or treatment of disorders associated with protein or peptide oligomers | |
US20230250094A1 (en) | Small molecule inhibitors of tdp-43 activity and uses thereof | |
Kalsoom et al. | Structure Dependent Differential Modulation of Aβ Fibrillization by Selenadiazole-Based Inhibitors | |
AU2021244941A1 (en) | Small molecules inducing the degradation of the cellular prion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Giese Armin Inventor after: WEBER PETRA Inventor after: Geissen Markus Inventor after: Groschup Martin H. Inventor after: Wagner Jens Inventor after: Bertsch Uwe Inventor after: Kretzschmar Hans Inventor after: Habeck Mathias Inventor after: Hirschberger Thomas Inventor after: Tavan Paul Inventor after: Griesinger Christian Inventor after: Leonov Andrei Inventor after: Ryazanov Sergey Inventor before: Giese Armin Inventor before: Weber Petra Inventor before: Geissen Markus Inventor before: Groschup Martin H. Inventor before: Wagner Jens Inventor before: Bertsch Uwe Inventor before: Kretzschmar Hans Inventor before: Habeck Mathias Inventor before: Hirschberger Thomas Inventor before: Tavan Paul Inventor before: Griesinger Christian Inventor before: Leonov Andrei Inventor before: Ryazanov Sergey |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: GIESE ARMIN BERTSCH UWE KRETZSCHMAR HANS HABECK MATHIAS HIRSCHBERGER THOMAS TAVAN PAUL GRIESINGER CHRISTIAN LEONOV ANDREI RYAZANOV SERGEY WEBER PETRA GEISSEN MARKUS GROSCHUP MARTIN H. WAGNER JENS TO: GIESE ARMIN BERTSCH UWE KRETZSCHMAR HANS HABECK MATHIAS HIRSCHBERGER THOMAS TAVAN PAUL GRIESINGER CHRISTIAN LEONOV ANDREI RYAZANOV SERGEY FRICK PETRA GEISSEN MARKUS GROSCHUP MARTIN H. WAGNER JENS |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |